DUBLIN, Ireland--(BUSINESS WIRE)--In response to Biogen Idec Inc.'s (“Biogen Idec”) announcement on December 12, 2007 that it has completed its strategic review and will continue its present course as an independent company, Elan Corporation, plc (“Elan”) today reaffirmed its commitment to TYSABRI and the patients who are and will benefit from this treatment. Specifically, Elan intends to continue to work effectively with Biogen Idec on securing FDA approval of the pending CD indication and realizing the full potential of TYSABRI in the MS marketplace.
